Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-spike antibody response to the COVID vaccine in lymphoma patients.
Della Pia A, Kim GYG, Ip A, Ahn J, Liu Y, Kats S, Koropsak M, Lukasik B, Contractor A, Amin K, Ayyagari L, Zhao C, Gupta A, Batistick M, Leslie LA, Goy AH, Feldman TA. Della Pia A, et al. PLoS One. 2022 Dec 1;17(12):e0266584. doi: 10.1371/journal.pone.0266584. eCollection 2022. PLoS One. 2022. PMID: 36454941 Free PMC article.
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
Lev-Ari S, Serzan M, Wu T, Ip A, Pascual L, Sinclaire B, Adams S, Marafelias M, Ayyagari L, Gill SK, Ma B, Zaemes JP, Della Pia A, Alaoui A, Madhavan S, Belouali A, Pecora A, Ahn J, Atkins MB, Shah NJ. Lev-Ari S, et al. Among authors: della pia a. Cancer. 2023 Jun 15;129(12):1885-1894. doi: 10.1002/cncr.34742. Epub 2023 Mar 23. Cancer. 2023. PMID: 36951119 Free article.
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A, Petrillo A, Della Pia A, Lee GG, Gill S, Varughese T, Zenreich J, Gutierrez M, Zhang J, Ahn J, Bharani V, Nejad AS, Pascual L, Feldman TA, Leslie LA, Goy AH. Ip A, et al. Among authors: della pia a. Leuk Lymphoma. 2023 Dec;64(14):2225-2235. doi: 10.1080/10428194.2023.2259528. Epub 2023 Dec 25. Leuk Lymphoma. 2023. PMID: 37740588 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 37785480
Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.
Danish A, Della Pia A, Fogel L, Alkhatatneh H, Zhao C, Varughese T, Al Feghali KA, Pascual L, Sinclaire B, Marafelias M, Zenreich J, Kuo YH, Feldman TA, Zhang Y, Goy AH, Ip A, Rowley SD. Danish A, et al. Among authors: della pia a. Front Oncol. 2024 Aug 19;14:1425506. doi: 10.3389/fonc.2024.1425506. eCollection 2024. Front Oncol. 2024. PMID: 39228984 Free PMC article.
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.
Shah NJ, Della Pia A, Wu T, Williams A, Weber M, Sinclaire B, Gourna Paleoudis E, Alaoui A, Lev-Ari S, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Serzan M, Cheruku D, Lee A, Sridhar A, Hee BTP, Ahn J, Pecora A, Ip A, Atkins MB. Shah NJ, et al. Among authors: della pia a. Cancers (Basel). 2024 Jun 14;16(12):2223. doi: 10.3390/cancers16122223. Cancers (Basel). 2024. PMID: 38927928 Free PMC article.
18 results